With the launch of a Monkey NGAL ELISA Kit, BioPorto completes its animal NGAL
product portfolio of high quality NGAL assays for animal research. With the new
Monkey NGAL ELISA Kit, a standard laboratory with conventional ELISA equipment
can analyze a variety of sample material. 

The monkey or non-human primate is an important experimental model for medical
research because of its close resemblance to human physiology. Pre-clinical
research in monkeys represents one of the final steps towards an approval that
will allow a pharmaceutical company to proceed to human clinical trials. NGAL
has been identified as one of the leading biomarkers to be applied for acute
kidney injury determination in human diagnostics and is therefore often
presented as an excellent candidate for the same use in the preclinical testing
industry. 

NGAL is the first “new” biomarker to be available for kidney safety and kidney
drug efficacy assessment in all major species used in drug development,
encompassing all the steps of drug development. 

The NGAL biomarker is in the process of becoming a recognized routine
diagnostic marker of acute kidney injury in humans. Influencing the
pharmaceutical industry alongside the diagnostic market can increase the rate
of market acceptance. 

The kidney biomarker NGAL

Every year about 13 million people are struck by acute kidney injury worldwide,
of whom about 4 million die. Nevertheless, there has been no real progress in
methods of diagnosing kidney injury over the last half century. Existing
methods, such as serum creatinine determination, only signal kidney failure
24-72 hours after the injury has taken place. In contrast, NGAL rises to
diagnostic levels within a few hours of kidney injury and thus enables the
physician to make vital clinical decisions before the damage progresses to
potentially fatal renal shutdown. In addition to helping the patient,
cost-benefit analyses show that implementing NGAL testing will contribute to
reducing hospital costs in the management of kidney injury and its
consequences. 

For further information please contact:

Thea Olesen, CEO

Christina Thomsen, Investor Relations

Tel. +45 45 29 00 00, mail investor@bioporto.com



About BioPorto

BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides
healthcare professionals in clinical and research settings a range of
diagnostic tests and antibodies. Our pioneering product portfolio includes
assays for underserved disease states such as NGAL for acute kidney injury. We
sell our products in more than 80 countries through diverse sales channels and
partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on
the NASDAQ OMX Copenhagen stock exchange.